Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market

1
Critical Care Therapeutics in Major Developed
Markets to 2020 - New and Late-Stage Four-Factor
PCCs and Recombinant Products to Drive Market
Single User License - 3500 Site User
License - 7000 Corporate User License -
10500 Publication Date - Jul 2014 Pages -
72 To know more details, email to
debora_at_reportstack.com
2
Summary

• This report provides in-depth analysis of the
  critical care market in the US, UK, France,
  Germany, Italy, Spain, Japan and Canada. The
  report provides an estimation of market size for
  2013, along with market forecasts to 2020. It
  covers critical care indications that are being
  treated using the five major plasma-derived
  products of albumin, anti-thrombin concentrates,
  factor XIII concentrates, fibrinogen
  concentrates, and prothrombin complex
  concentrates.
• The total value of the critical care market in
  the major developed markets was estimated at 1.8
  billion in 2013 and is expected to grow at a
  Compound Annual Growth Rate (CAGR) of 4.7 to
  2.5 billion in 2019. This growth is attributed
  to the recent approval of new factor concentrates
  in the US that are expected to witness increasing
  uptake in the forecast period. Factor
  concentrates are increasingly preferred due to
  their lower infection risks over older
  alternatives such as FFP and cryoprecipitate in
  critical care settings.

3
Scope
- A brief introduction to the five major
plasma-derived products in critical care and the
indications that they are being used to treat, as
well as disease overview, epidemiology, other
treatment options, and treatment patterns-
Analysis of major marketed products in critical
care, covering product performance in terms of
the safety and efficacy of recent approvals- A
review of the critical care pipeline, including
individual analysis of promising late-stage
pipeline drugs that are most likely to enter the
market during the forecast period-
Multi-scenario forecasts of the critical care
market over the 20132020 period in the eight
major developed markets- Key drivers and
restraints that have had and are expected to have
a significant impact on the market
4
Key Benefits
- Align your product portfolio to markets with
high growth potential- Develop market entry and
expansion strategies by identifying the regions
and therapeutic segments poised for strong
growth- Devise effective, tailored strategies
for each country through the understanding of key
drivers and barriers in the critical care drugs
market- Develop key strategic initiatives based
on an understanding of key focus areas and
leading companies- Accelerate and strengthen
your market position by identifying key companies
for mergers, acquisitions and strategic
partnerships.
5
If you are interested...
Contact Debora White Email
debora_at_reportstack.com Ph1-888-789-6604 http/
/www.reportstack.com